Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Mauro

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The Oncologist|June 26, 2001
STI571: targeting BCR-ABL as therapy for CMLM J Mauro, B J Druker
Current Oncology Reports|April 11, 2001
STI571: a gene product-targeted therapy for leukemiaM J Mauro, B J Druker
Current Opinion in Oncology|January 10, 2001
Chronic myelogenous leukemiaM J Mauro, B J Druker
Cancer Chemotherapy and Pharmacology|October 6, 2001
ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapyM J Mauro, M E O'Dwyer, B J Druker
Leukemia|March 6, 2013
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysisF J Giles, M J Mauro, F Hong, et al.
Leukemia|June 30, 2015
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phaseT P Hughes, G Saglio, A Quintás-Cardama, et al.
Leukemia|March 21, 2003
Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylateM E O'Dwyer, K M Gatter, M Loriaux, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The Oncologist|June 26, 2001
STI571: targeting BCR-ABL as therapy for CMLM J Mauro, B J Druker
Current Oncology Reports|April 11, 2001
STI571: a gene product-targeted therapy for leukemiaM J Mauro, B J Druker
Current Opinion in Oncology|January 10, 2001
Chronic myelogenous leukemiaM J Mauro, B J Druker
Cancer Chemotherapy and Pharmacology|October 6, 2001
ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapyM J Mauro, M E O'Dwyer, B J Druker
Leukemia|March 6, 2013
Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysisF J Giles, M J Mauro, F Hong, et al.
Leukemia|June 30, 2015
BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phaseT P Hughes, G Saglio, A Quintás-Cardama, et al.
Leukemia|March 21, 2003
Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylateM E O'Dwyer, K M Gatter, M Loriaux, et al.
Pageof 1